Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 104

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 104
---
)(59,950)(67,144)Tebentafusp programs(11,789)(8,315)(30,196)(18,766)Infectious disease programs(1,347)(1,324)(4,077)(5,009)All other external clinical and preclinical costs(15,551)(6,361)(42,035)(17,309)Total external R&D expenses(50,654)(34,512)(136,258)(108,228)R&D salaries and other employee-related costs(11,932)(11,272)(35,882)(33,247)Selling, general and administrative (SG&A) salaries and other employee-related costs(14,038)(11,783)(39,083)(37,104)Other SG&A expenses(18,071)(19,009)(60,992)(56,801)Other segment (expense) income, net (a)(8,662)5,512 (26,393)(15,685)Segment and consolidated net (loss) income$(177)$8,736 $(5,454)$(27,316)(a) Other segment expenses, net includes other internal R&D expenses, share-based compensation expense, R&D tax credits, interest income, interest expense, foreign currency gain, other income, net and income tax expense (benefit).

14

10. Commitments and contingencies

Lease commitments The maturities of operating lease liabilities as of September 30, 2025 were as follows (in thousands):Remainder of 2025$1,451 20265,876 20275,786 20285,476 20295,205 2030 and thereafter48,949 Total lease payments72,743 Less imputed interest(29,468)Present value of operating lease liabilities$43,275 Future lease commitments - leases not yet commenced$2,973 Future lease commitments - leases not yet commencedThe Company has entered into a non-cancellable lease agreement for premises that will commence in 2028 and end in 2031, with total future minimum lease payments of $3.0 million. This amount is not included in the present value of operating lease liabilities above as the lease had not commenced as of September 30, 2025.Lease commencement during the periodDuring the nine months ended September 30, 2025, the Company commenced a new operating lease and recognized a non‑cash right‑of‑use asset